Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurobiology
Biotech
BioAge axes obesity asset over liver toxicity
Weeks after stopping a phase 2 trial, the biotech has jettisoned the molecule and shifted its focus to a preclinical neuroinflammation prospect.
Nick Paul Taylor
Jan 28, 2025 10:11am
Brain atlas unveils dozens of cell types that control movement
Oct 11, 2021 8:44am
Sunovion pens $890M Otsuka neuropsychiatric drug pact
Sep 30, 2021 7:50am
How an old antipsychotic might treat brain, spinal cord injuries
May 14, 2020 11:00am
After Kerrisdale attack, Prothena dumps AL amyloidosis drug
Apr 23, 2018 8:57am
Roche pens drug discovery pact with Confo
Dec 19, 2017 9:13am
